KB-1529

ABBV066-hIgG1

52640

Home » ABBV066-hIgG1

Background of ABBV066-hIgG1

Risankizumab (Skyrizi®; risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (in the EU), those who are candidates for systemic therapy or phototherapy (in the USA) and those who have an inadequate response to conventional therapies (in Japan).

Specifications

Catalog Number	KB-1529
Antibody Name	ABBV066-hIgG1
Isotype	Human IgG1, kappa
FC Muations	Wild Type
Target	P19
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Blair HA. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. Drugs. 2020 Aug;80(12):1235-1245. doi: 10.1007/s40265-020-01357-1. Erratum in: Drugs. 2020 Sep;80(14):1505. doi: 10.1007/s40265-020-01392-y. PMID: 32632826; PMCID: PMC7475056.